Why the study?
Does imidapril or candesartan cilexetil prevent L-NAME-induced cardiac PAI-1 expression in rats?
Does imidapril or candesartan cilexetil prevent L-NAME-induced cardiac PAI-1 expression in rats?
Imidapril, but not candesartan cilexetil, prevents L-NAME-induced cardiac PAI-1 expression in rats, suggesting differential effects of ACE inhibition and AT1 antagonism in vivo.
Caution against clinical extrapolation; leaves open whether ACE inhibition uniquely modulates PAI-1 beyond AT1 blockade in humans.
We investigated effects of the angiotensin-converting enzyme (ACE) inhibitor imidapril and the angiotensin II type 1 (AT1) antagonist candesartan cilexetil on cardiac plasminogen activator inhibitor-1 (PAI-1) expression in rats. Cardiac PAI-1 mRNA levels were increased after a 7-day treatment with the nitric oxide (NO) synthesis inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME). PAI-1 immunoreactivity was increased in the coronary arteries. Treatment with imidapril significantly prevented the L-NAME-induced increase in the gene expression and immunoreactivity of PAI-1, but candesartan cilexetil showed no such effect. This study provides the first evidence of differential effects of ACE inhibition and AT1 antagonism on cardiac PAI-1 expression in vivo.
No takes yet. Share an insight, caveat, or question.
Katoh et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: